Siegfried Ussar

Dr. Siegfried Ussar


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2008 in Nature Medicine
Verified
Journal Article
Closed access
MMMarkus Moser
Markus Moser
BNBernhard Nieswandt
Bernhard Nieswandt
SUSiegfried Ussar
Siegfried Ussar
MPMiroslava Požgajová
Miroslava Požgajová
RFReinhard Fässler
Reinhard Fässler

1 July 2008 in Cell
Verified
Journal Article
Closed access
MKMarcus Krüger
Marcus Krüger
MMMarkus Moser
Markus Moser
SUSiegfried Ussar
Siegfried Ussar
ITIngo Thievessen
Ingo Thievessen
CLChristian A. Luber
Christian A. Luber
MMMatthias Mann
Matthias Mann

1 September 2015 in Cell Metabolism
Verified
Journal Article
Closed access
SUSiegfried Ussar
Siegfried Ussar
NGNicholas W. Griffin
Nicholas W. Griffin
OBOlivier Bezy
Olivier Bezy
SFShiho Fujisaka
Shiho Fujisaka
SVSara Vienberg
Sara Vienberg
CKC. Ronald Kahn
C. Ronald Kahn

15 May 2008 in Genes & Development
Verified
Journal Article
Open access
PDF file
EMEloi Montanez
Eloi Montanez
SUSiegfried Ussar
Siegfried Ussar
MSMartina Schifferer
Martina Schifferer
MBMichael Bösl
Michael Bösl
RZRoy Zent
Roy Zent
RFReinhard Fässler
Reinhard Fässler
Control of integrin activation is required for cell adhesion and ligand-induced signaling. Here we report that loss of the focal adhesion protein Kindlin-2 in mice results in peri-implantation lethality caused by severe detachment of the endoderm and epiblast from the basement membrane. We found that Kindlin-2-deficient cells were unable to activate their integrins and that Kindlin-2 is required for talin-induced integrin activation. Furthermore, we demonstrate that Kindlin-2 is required for integrin outside-in signaling to enable firm adhesion and spreading. Our findings provide evidence that Kindlin-2 is a novel and essential element of bidirectional integrin signaling.

22 February 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LSLena Svensson
Lena Svensson
KHKimberley Howarth
Kimberley Howarth
AMAlison McDowall
Alison McDowall
IPIrene Patzak
Irene Patzak
RERachel Evans
Rachel Evans
NHNancy Hogg
Nancy Hogg

14 February 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
KLKevin Lee
Kevin Lee
SRSteven J. Russell
Steven J. Russell
SUSiegfried Ussar
Siegfried Ussar
JBJeremie Boucher
Jeremie Boucher
CVCecile Vernochet
Cecile Vernochet
CKC. Ronald Kahn
C. Ronald Kahn
Conditional gene targeting has been extensively used for in vivo analysis of gene function in adipocyte cell biology but often with debate over the tissue specificity and the efficacy of inactivation. To directly compare the specificity and efficacy of different Cre lines in mediating adipocyte specific recombination, transgenic Cre lines driven by the adipocyte protein 2 (aP2) and adiponectin (Adipoq) gene promoters, as well as a tamoxifen-inducible Cre driven by the aP2 gene promoter (iaP2), were bred to the Rosa26R (R26R) reporter. All three Cre lines demonstrated recombination in the brown and white fat pads. Using different floxed loci, the individual Cre lines displayed a range of efficacy to Cre-mediated recombination that ranged from no observable recombination to complete recombination within the fat. The Adipoq-Cre exhibited no observable recombination in any other tissues examined, whereas both aP2-Cre lines resulted in recombination in endothelial cells of the heart and nonendothelial, nonmyocyte cells in the skeletal muscle. In addition, the aP2-Cre line can lead to germline recombination of floxed alleles in ∼2% of spermatozoa. Thus, different “adipocyte-specific” Cre lines display different degrees of efficiency and specificity, illustrating important differences that must be taken into account in their use for studying adipose biology.